11 / 38
Phase III CHAARTED Trial Long-term Follow-up:
High-Volume vs Low-Volume Disease
Median follow-up of 53.7 mos in patients with metastatic hormone-sensitive prostate cancer randomized to
ADT + docetaxel vs ADT alone (N = 790)
High-Volume Disease
Low-Volume Disease
Kyriakopoulos CE, et al. J Clin Oncol. 2018;36:1080-1087.